PACLITAXEL protein-bound particles for injectable suspension (albumin-bound), for intravenous use	powder containir particles in single
Initial U.S. Approval: 2005	Neutrophil cour
WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning.	Severe hyperse cles for injectat
 Do not administer paclitaxel protein-bound particles for inject- able suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm³. (4) Monitor for neutropenia, which may be severe and result in infection or sepsis. (5.1, 5.3) Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound). (5.1, 5.3) 	 Sensory neurop tion or treatmer Sepsis occurr received paclit sion (albumin-t paclitaxel pro (albumin-bour
	neutropenia, un treatment at rea
Dosage and Administration (2.1, 2.7) 8/2020 Contraindications (4) 8/2020 Warnings and Precautions (5.1, 5.2) 8/2020	 Pneumonitis o particles for inj with gemcitabin protein-bound
INDICATIONS AND USAGE	and gemcitabir • Severe hypers
 Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3) 	 reported. Do not Exposure and thepatic impairs patients with h Paclitaxel prote bound) contair theoretical ris Paclitaxel prote (albumin-boun tial risk to a fer 8.3)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use

PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE

prescribing information for PACLITAXEL PROTEIN-BOUND PARTI-CLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND).

SUSPENSION (ALBUMIN-BOUND) safely and effectively. See ful

------ DOSAGE AND ADMINISTRATION -------• Do not substitute paclitaxel protein-bound particles for injectable suspension (albumin-bound) for other paclitaxel products. (2.1) Extravasation: Closely monitor the infusion site for extravasation and infiltration (2

- Metastatic Breast Cancer (MBC): Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 60 mg/m² intravenously over 30 minutes every 3 weeks. (2.2) · Non-Small Cell Lung Cancer (NSCLC): Recommended dosage of bound particles for injectable suspension (albuminbound) is 100 mg/m² intravenously over 30 minutes on Days 1, 8. and 15 of each 21-day cycle: administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound). (2.2)
- · Adenocarcinoma of the Pancreas: Recommended dosage of paclitaxel protein-bound particles for injectable suspension (albu min-bound) is 125 mg/m² intravenously over 30-40 minutes on Days 1 8. and 15 of each 28-day cycle: administer gemcitabine on Days 1. 8. and 15 of each 28-day cycle immediately after paclitaxel proteinbound particles for injectable suspension (albumin-bound). (2.4) <u>Use in Patients with Hepatic Impairment:</u> Paclitaxel protein-bound
- particles for injectable suspension (albumin-bound) is not recommended for use in patients with AST > 10 x ULN; or bilirubin > 5 x ULN or with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment. For MBC or NSCLC, reduce starting dose in patients with moderate to severe hepatic impairment.
- **FULL PRESCRIBING IN** WARNING: SEVERE MY
- 1 INDICATIONS AND 1.1 Metastatic Brea 1.2 Non-Small Cel
- 1.3 Adenocarcinoma
- DOSAGE AND ADM
- Important Adm Recommende 3 Recommended 4 Recommended 2.5 Dosage Modific
- 2.6 Dosage Modific .7 Preparation for 2.8 Stability
- 3 DOSAGE FORMS A
- 4 CONTRAINDICATIO 5 WARNINGS AND PE
- 1 Severe Myelosu
- .2 Severe Neuropa
- 4 Pneumonitis .5 Severe Hyperse
- 5.6 Use in Patients 5.7 Albumin (Huma
- 5.8 Embryo-Fetal Te
- 6 ADVERSE REACTIO 6.1 Clinical Trials E
- 6.2 Postmarketing

FULL PRESCRIBING IN Paclitaxel Protein-Bo

- (albumin-bound) WARNING Do not administer injectable suspens with baseline neutr [see Contraindicatio
- Monitor for neutrol infection or sepsis Perform frequent co receiving paclitaxe suspension (albumi (5.1, 5.3)].
- INDICATIONS AND
- 1.1 Metastatic Breast Paclitaxel protein (albumin-bound) is after failure of com or relapse within (therapy should hav contraindicated.
- 1.2 Non-Small Cell Lun Paclitaxel protein-bo min-bound) is inc advanced or metas with carboplatin, in surgery or radiation
- 1.3 Adenocarcinoma o Paclitaxel protein-bo min-bound) is indic metastatic adenoca
- gemcitabine.

- Dose Reductions for Adverse Reactions: Dose reductions or disconnuation may be needed based on severe hematologic, neurologic, cutaneous, or gastrointestinal toxicities, (2.6) -DOSAGE FORMS AND STRENGTHS — For injectable suspension: white to yellow, sterile, lyophilized
- powder containing 100 mg of paclitaxel formulated as albumin-bound le-dose vial for reconstitution. (3) - CONTRAINDICATIONS unts of < 1.500 cells/mm³. (4)
- sensitivity reactions to paclitaxel protein-bound partiable suspension (albumin-bound). (4) WARNINGS AND PRECAUTIONS -----
- opathy occurs frequently and may require dose reducent interruption. (5.2) rred in patients with or without neutropenia who litaxel protein-bound particles for injectable suspen--bound) in combination with gemcitabine; interrupt rotein-bound particles for injectable suspension und) and gemcitabine until sepsis resolves, and if
- until neutrophils are at least 1500 cells/mm³, then resume educed dose levels. (5.3) occurred with the use of paclitaxel protein-bound njectable suspension (albumin-bound) in combination ine; permanently discontinue treatment with paclitaxel d particles for injectable suspension (albumin-bound)
- ine. (5.4) rsensitivity reactions with fatal outcome have been not rechallenge with this drug. (4, 5.5) toxicity of paclitaxel can be increased in patients with
- irment, consider dose reduction and closely monitor nepatic impairment. (2.5, 5.6) ein-bound particles for injectable suspension (albumin-
- ins albumin derived from human blood, which has a isk of viral transmission. (5.7) rotein-bound particles for injectable suspension and) can cause fetal harm. Advise patients of potenfetus and to use effective contraception. (5.8, 8.1,
- ----- ADVERSE REACTIONS ------• The most common adverse reactions (\geq 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea, (6.1) The most common adverse reactions ($\geq 20\%$) in NSCLC are anemia.
- neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue. (6.1) The most common (> 20%) adverse reactions of paclitaxel proteinbound particles for injectable suspension (albumin-bound) in adenocarcinoma of the pancreas are neutropenia, fatigue, peripheral
- neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia. vomiting decreased appetite, rash, and dehydration, (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
- ----- DRUG INTERACTIONS ------Use caution when concomitantly administering Paclitaxel proteinbound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. (7)
- Lactation: Advise not to breastfeed. (8.2)
- See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 8/2020

	Revised: 8/2020	sion (albur Resume pa	nin-bound clitaxel pro	otein-bound particle I) for Grade 3-4 otein-bound particle	periphera es for injec	I neuropathy stable suspen
INFORMATION: CONTENTS* MYELOSUPPRESSION	7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS	sion (albun Table 2) w	hin-bound) hen perip) and carboplatin heral neuropathy i [see Warnings and	at reduce mproves t	d doses (se o Grade 1 o
D USAGE bast Cancer Il Lung Cancer	8.1 Pregnancy8.2 Lactation8.3 Females and Males of Reproductive Potential	Adverse Rea Table 2: Pe	a <i>ctions (6.</i> r manent E	1)]. Dose Reductions fo Adverse Reactions	or Hemato	logic and
ma of the Pancreas MINISTRATION ninistration Instructions d Dosage for Metastatic Breast Cancer d Dosage for Non-Small Cell Lung Cancer	 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 10 OVERDOSAGE 	Adverse Reactio		ence Weekly Par protein-bound for injectable s (albumin-bou (mg/m	clitaxel l particles uspension nd) Dose	Every 3-Week Carboplatin Dose (AUC mg∙min/mL)
d Dosage for Adenocarcinoma of the Pancreas	11 DESCRIPTION	Neutropenic Feve	er Firs		• ,	4.5
ications for Hepatic Impairment ications for Adverse Reactions r Intravenous Administration	12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action	(ANC less than 500/mm ³ with fev >38°C)				3
AND STRENGTHS IONS PRECAUTIONS suppression pathy	 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Metastatic Breast Cancer 	OR Delay of next cyc by more than 7 da for ANC less than 1500/mm ³ OR ANC less than 50 mm ³ for more tha 7 days	ys Thir 0/	d Disco	ontinue Trea	tment
	14.2 Non-Small Cell Lung Cancer 14.3 Adenocarcinoma of the Pancreas		Firs	t 75		4.5
sensitivity	15 REFERENCES	Platelet count less than 50,000/mm ³	S Seco		ontinue Trea	_
s with Hepatic Impairment nan)	16 HOW SUPPLIED/STORAGE AND HANDLING				fillinue frea	
Toxicity	17 PATIENT COUNSELING INFORMATION	Severe sensory	Firs	-		4.5
IONS Experience	* Sections or subsections omitted from the full prescribing information	Neuropathy – Grade 3 or 4	Seco			3
g Experience	are not listed.		Thir		ontinue Trea	tment
INFORMATION ound Particles for Injectable Suspension	2 DOSAGE AND ADMINISTRATION		reduction	<u>ne Pancreas</u> s for patients with ed in Tables 4 and 5		
ound Particles for injectable Suspension	2.1 Important Administration Instructions DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS. Paclitaxel protein-bound particles for inject-	Table		Level Reductions f arcinoma of the P		s with
G: SEVERE MYELOSUPPRESSION er paclitaxel protein-bound particles for usion (albumin-bound) therapy to patients trophil counts of less than 1,500 cells/mm ³	able suspension (albumin-bound) has different dosage and administration instructions from other paclitaxel products. Closely monitor the infusion site for extravasation or drug infil-	Dose Level		Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (mg/m ²)		Gemcitabine (mg/m²)
ions (4)].	tration during administration. Limiting the infusion of paclitaxel protein-bound particles for injectable suspension (albumin-bound)	Full dose 1 st dose reduction 2 nd dose reduction If additional dose reduction required		125		1000
openia, which may be severe and result in [see Warnings and Precautions (5.1, 5.3)].	to 30 minutes may reduce the risk of infusion-related reactions [see Adverse Reactions (6.2)].			100		800
complete blood cell counts on all patients el protein-bound particles for injectable	Consider premedication in patients who have had prior hypersen-			75 Discontinue		600 Discontinue
nin-bound) [see Warnings and Precautions	sitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). Do not re-challenge patients who experience a severe hypersensitivity reaction to paclitaxel protein-					
ID USAGE t Cancer n-bound particles for injectable suspension is indicated for the treatment of breast cancer nbination chemotherapy for metastatic disease 6 months of adjuvant chemotherapy. Prior ave included an anthracycline unless clinically	 bound particles for injectable suspension (albumin-bound) [see Contraindications (4) and Warnings and Precautions (5.5)]. 2.2 Recommended Dosage for Metastatic Breast Cancer After failure of combination chemotherapy for metastatic breast cancer or relapse within 6 months of adjuvant chemotherapy, the recommended regimen for paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 260 mg/m² administered intravenously over 30 minutes every 3 weeks. 	bocytopeni are provide Table 4: Dose F and/or Thromb	a for patie d in Table Recommen	modifications for ents with adenocar 4. Indation and Modifie a at the Start of a Adenocarcinoma c	cinoma of cations for Cycle or w	the pancrea Neutropenia ithin a Cycle
ung Cancer bound particles for injectable suspension (albu- dicated for the first-line treatment of locally static non-small cell lung cancer, in combination	 2.3 Recommended Dosage for Non-Small Cell Lung Cancer The recommended dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 100 mg/m² adminis- tered as an intravenous infusion over 30 minutes on Days 1, 8, and 	Cycle AN0 Day (cells/r		Platelet count (cells/mm³)	particles suspens	protein-bound for injectable ion (albumin- Gemcitabine
in patients who are not candidates for curative on therapy.	15 of each 21-day cycle. Administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles	Day 1 < 150	00 OR	R < 100,000 Delay doses until reco		es until recovery
of the Pancreas bound particles for injectable suspension (albu- icated for the first-line treatment of patients with	 for injectable suspension (albumin-bound) [see Clinical Studies (14.2)]. 2.4 Recommended Dosage for Adenocarcinoma of the Pancreas 	Day 8 500 to	00 OR	50,000 to < 75,000	0,000 to < 75,000 Reduce 1 dose level	
carcinoma of the pancreas, in combination with	The recommended dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is 125 mg/m ² administered	< 500	OR	< 50,000	Withh	old doses
nedicine for cancer. axel protein- table suspen-) is safe or is safe or injectable ount is below	e suspension e suspension paclitaxel es for inject- min-bound), ovider about conditions, on to ataxane. n to become rotein-bound e suspension n harm your e to become e to become	are pregnant eatment with bound parti- suspension	int and for at ifter the last	able suspen- d). ffective birth btion) during for at least six	dose of paci- l particles for on (albumin-	ir heatincare irth control se during this

APOTEX CORP.

Paclitaxel protein-bound particles

Rx only

PACAPOPI.012/PPI.012 8/2020 Revised: August 2020

for injectable suspension

(Patient Information Enclosed)

(albumin-bound)

as an intravenous infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. Administer gemcitabine immediately after paclitaxel protein-bound particles for injectable suspension (albumin-bound) on Days 1, 8, and 15 of each 28-day cycle [see Clinical Studies (14.3)]. 2.5 Dosage Modifications for Hepatic Impairment

For patients with moderate or severe hepatic impairment, reduce the starting dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) as shown in Table 1 Table 1: Recommendations for Starting Dose in Patients

				tic Impairm		
		Bilirubin	Paclitaxel protein-bound particles for injectable suspension (albumin-bound) Dose ^a			
AST Levels		Levels	MBC NSCLC • Adenocarcinom of Pancreas •			
< 10 x ULN	AND	> 1.5 to ≤ 3 x ULN	200 mg/m² b	80 mg/m² ь	not recommended	
< 10 x ULN	AND	> 3 to ≤ 5 x ULN	200 mg/m² b	80 mg/m²ь	not recommended	
> 10 x ULN	OR	> 5 x ULN	not recommended	not recommended	not recommended	

AST = Aspartate Aminotransferase; MBC = Metastatic Breast Cancer; NSCLC = Non-Small Cell Lung Cancer; ULN = Upper limit of normal. sage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance.

A dose increase to 260 mg/m² for patients with metastatic breast cancer or 100 mg/m² for patients with non-small cell lung cancer in ubsequent courses should be considered if the patient tolerates the reduced dose for two cycles. Patients with bilirubin levels above the upper limit of normal were

excluded from clinical trials for pancreatic or lung cancer. 2.6 Dosage Modifications for Adverse Reactions

Metastatic Breast Cancer atients who experience severe neutropenia (neutrophils less than 500 cells/mm³ for a week or longer) or severe sensory neuropathy

during paclitaxel protein-bound particles for injectable suspension albumin-bound) therapy should have dosage reduced to 220 mg/m for subsequent courses of paclitaxel protein-bound particles for injectable suspension (albumin-bound). For recurrence of severe eutropenia or severe sensory neuropathy, additional dose reduction should be made to 180 mg/m². For Grade 3 sensory neuropathy hold treatment until resolution to Grade 1 or 2, followed by a dose reduction for all subsequent courses of paclitaxel proteinpound particles for injectable suspension (albumin-bound) *[see* Contraindications (4), Warnings and Precautions (5.1, 5.2) and Adverse Reactions (6.1)].

Non-Small Cell Lung Cance Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm³ and platelet count is at least 100,000 cells/mm³ [see Contraindications (4). Warnings and Precautions (5.1) and Adverse Reactions (6.1). In patients who develop severe neutropenia or thrombocytopenia withhold treatment until counts recover to an absolute neutrophil ount of at least 1500 cells/mm³ and platelet count of at least 100,000 cells/mm³ on Day 1 or to an absolute neutrophil count of at least 500 cells/mm³ and platelet count of at least 50,000 cells/mm³ on Davs 8 or 15 of the cycle. Upon resumption of

dosing, permanently reduce paclitaxel protein-bound particles for njectable suspension (albumin-bound) and carboplatin doses as outlined in Table 2. Withhold paclitaxel protein-bound particles for injectable suspen-

Table 4: Dose Recommendation and Modifications for Neutropenia and/or Thrombocytopenia at the Start of a Cycle or within a Cycle for Patients with Adenocarcinoma of the Pancreas (Continued

Cycle Day	ANC (cells/mm³)		Platelet count (cells/mm ³)	Paclitaxel protein-bound particles for injectable suspension (albumin- bound) / Gemcitabine
Day 1	5: If Day 8 do	oses w	vere reduced or give	n without modification:
	500 to < 1000	OR	50,000 to < 75,000	Reduce 1 dose level from Day 8
	< 500	OR	< 50,000	Withhold doses
	Day	15: lf	Day 8 doses were w	vithheld:
	≥ 1000	OR	≥ 75,000	Reduce 1 dose level from Day 1
	500 to < 1000	OR	50,000 to < 75,000	Reduce 2 dose levels from Day 1
	< 500	OR	< 50,000	Withhold doses

Recommended dose modifications for other adverse reactions in patients with adenocarcinoma of the pancreas are provided in

Table 5: Dose Modifications for Other Adverse Reactions in Patients with Adenocarcinoma of the Pancreas

Paclitaxel protein-bound particles for injectable suspension (albumin-bound)			
Withhold until fever resolves and ANC ≥ 1500; resume at next lower dose level			
Withhold until improves to ≤ Grade 1; resume at next lower dose level			
Reduce to next lower dose level; discontinue treatment if toxicity persists			
a Withhold until improves to ≤ Grade 1; resume at next lower dose level			
	particles for injectable suspension (albumin-bound) Withhold until fever resolves ≥ 1500; resume at next lowe Withhold until improves to ≤ Grade 1; resume at next lower dose level Reduce to next lower dos discontinue treatment if toxic		

7 Preparation for Intravenous Administration

el protein-bound particles for injectable suspension (albumin bound) is a cytotoxic drug. Follow applicable special handling nd disposal procedures.¹ The use of gloves is recommended f paclitaxel protein-bound particles for injectable suspension lbumin-bound) (lyophilized cake or reconstituted suspension) contacts the skin, wash the skin immediately and thoroughly with soap and water. Following topical exposure to paclitaxe events may include tingling, burning, and redness. If paclitaxel otein-bound particles for injectable suspension (albumin-l ntacts mucous membranes, the membranes should be flushed

thoroughly with water. Paclitaxel protein-bound particles for injectable suspension (albuminbound) is supplied as a sterile lyophilized powder for reconstitution before use.

Read the entire preparation instructions prior to reconstitution. Aseptically, reconstitute each vial by injecting 20 mL of 0.9% Sodium Chloride Injection, USP.

Slowly inject the 20 mL of 0.9% Sodium Chloride Injection, USP over a minimum of 1 minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF THE VIAL.



3. DO NOT INJECT the 0.9% Sodium Chloride Injection, USP, directly onto the lyophilized cake as this will result in foaming. 4. Once the injection is complete, allow the vial to sit for a minimum

of 5 minutes to ensure proper wetting of the lyophilized cake/ 5. Gently swirl and/or invert the vial slowly for at least 2 minutes until

complete dissolution of any cake/powder occurs. Avoid generation of foam. 6. If foaming or clumping occurs, stand solution for at least 15 minutes until foam subsides.

Each mL of the reconstituted formulation will contain 5 mg/mL

The reconstituted suspension should be milky and homogenous without visible particulates. If particulates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Discard the reconstituted suspension if precipitates are observed. Discard any unused portion. Calculate the exact total dosing volume of 5 mg/ml susp required for the patient and slowly withdraw the dosing volume of the reconstituted suspension from the vial(s) into a syringe: Dosing volume (mL)=Total dose (mg)/5 (mg/mL). Inject the appropriate amount of reconstituted paclitaxel protein bound particles for injectable suspension (albumin-bound) into an empty, sterile intravenous bag [plasticized polyvinyl chloride (PVC) containers, PVC or non-PVC type intravenous bag]. The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) infusions. The use of medical devices containing silicone oil as a lubricant (i.e.

syringes and intravenous bags) to reconstitute and administer pacltaxel protein-bound particles for injectable suspension (albuminbound) may result in the formation of proteinaceous strands. Visually inspect the reconstituted paclitaxel protein-bound particles for injectable suspension (albumin-bound) suspension in the intravenous bag prior to administration. Discard the reconstituted suspension if proteinaceous strands, particulate matter, or discoloration are observed.

2.8 Stability Unopened vials of paclitaxel protein-bound particles for injectable suspension (albumin-bound) are stable until the date indicated on the package when stored between 20°C to 25°C (68°F to 77°F) in the original package. Neither freezing nor refrigeration adversely affects the stability of the product.

Stability of Reconstituted Suspension in the Vial Reconstituted paclitaxel protein-bound particles for injectable suspension (albumin-bound) in the vial should be used immediately, but may be refrigerated at 2°C to 8°C (36°F to 46°F) for a

maximum of 24 hours if necessary. If not used immediately, each vial of reconstituted suspension should be replaced in the original carton to protect it from bright light. Discard any unused portion. Stability of Reconstituted Suspension in the Infusion Bag The suspension for infusion when prepared as recommended in

ated at 2°C to $\tilde{8}$ °C (36°F to 46°F) and protected from bright light for a maximum of 24 hours. The total combined refrigerated storage time of reconstituted paclaxel protein-bound particles for injectable suspension (albumin bound) in the vial and in the infusion bag is 24 hours. This may be followed by storage in the infusion bag at ambient temperature (approximately 25°C) and lighting conditions for a maximum of

4 hours.

Discard any unused portion.

an infusion bag should be used immediately, but may be refriger-

DOSAGE FORMS AND STRENGTHS or injectable suspension, for intravenous use: white to yellow, sterile

- lyophilized powder containing 100 mg of paclitaxel formulated as albumin-bound particles in single-dose vial for reconstitution. CONTRAINDICATIONS Paclitaxel protein-bound particles for injectable suspension
- (albumin-bound) is contraindicated in patients with: • Baseline neutrophil counts of < 1.500 cells/mm³ [see Warnings and Precautions (5.1)] • A history of severe hypersensitivity reactions to paclitaxel proteinbound particles for injectable suspension (albumin-bound) [see

Warnings and Precautions (5.5) WARNINGS AND PRECAUTIONS

5.1 Severe Myelosuppression Severe myelosuppression (primarily neutropenia) is dose-depen dent and a dose-limiting toxicity of paclitaxel protein-bound parti cles for injectable suspension (albumin-bound). In clinical studies, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC), 47% of patients with non-small cell lung cancer (NSCLC), and 38% of patients with pancreatic cancer. Monitor for severe neutropenia and thrombocytopenia by performing complete blood cell counts frequently, including prior to dosing on Day 1 (for MBC) and Days 1, 8, and 15 (for NSCLC and for pancreatic cancer). Do not administer paclitaxel protein-

bound particles for injectable suspension (albumin-bound) to patients with baseline absolute neutrophil counts (ANC) of less than 1.500 cells/mm³ [see Contraindications (4)]. In the case of severe neutropenia (<500 cells/mm³ for seven days or more) during a course of paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy, reduce the dose

of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in subsequent courses in patients with either MBC or NSCLC In patients with MBC, resume treatment with every-3-week cycles of paclitaxel protein-bound particles for injectable suspension (albumin-bound) after ANC recovers to a level >1.500 cells/mm³ and platelets recover to a level >100,000 cells/mm³. In patients with

NSCLC, resume treatment if recommended at permanently reduced doses for both weekly paclitaxel protein-bound particles for inject able suspension (albumin-bound) and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm³ and platelet count of at least 100.000 cells/mm³ on Day 1 or to an ANC of at least 500 cells/mm³ and platelet count of at least 50,000 cells/mm³ on Days 8 or 15 of the cycle [see Dosage and Administration (2.6)]. In patients with adenocarcinoma of the pancreas, withhold paclitaxel protein-bound particles for injectable suspension (albumin-

bound) and gemcitabine if the ANC is less than 500 cells/mm³ or platelets are less than 50,000 cells/mm³ and delay initiation of the next cycle if the ANC is less than 1500 cells/mm³ or platelet count is less than 100.000 cells/mm³ on Day 1 of the cycle. Resume treatment with appropriate dose reduction if recommended (see Dosage and Administration (2.6)1.

Severe Neuropathy nsory neuropathy is dose- and schedule-dependent (see Adverse *Reactions (6.1)*. If \geq Grade 3 sensory neuropathy develops. withhold paclitaxel protein-bound particles for injectable suspension (albumin-bound) treatment until resolution to Grade 1 or 2 metastatic breast cancer or until resolution to \leq Grade 1 for NSCLC and pancreatic cancer followed by a dose reduction for all subsequent courses of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Dosage and Administration (2.6)].

i.3 Sepsis Sepsis occurred in 5% of patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine. Biliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis. If a patient becomes febrile (regardless of ANC) initiate treatment with

broad spectrum antibiotics. For febrile neutropenia, interrupt paclitaxel protein-bound particles for injectable suspension (albuminbound) and gemcitabine until fever resolves and ANC \geq 1500. then resume treatment at reduced dose levels [see Dosage and Administration (2.6)] 5.4 Pneumonitis

Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with

Monitor patients for signs and symptoms of pneumonitis and interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine during evaluation of suspected oneumonitis. After ruling out infectious etiology and upon making a diagnosis of pneumonitis, permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe Hypersensitivity

Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported. Do not rechallenge patients who experience a severe hypersensitivity reaction to pack itaxel protein-bound particles for injectable suspension (albuminbound) with this drug [see Contraindications (4)]. ty between naclitaxel protein-h for injectable suspension (albumin-bound) and other taxane products has been reported and may include severe reactions such as anaphylaxis. Closely monitor patients with a previous history of persensitivity to other taxanes during initiation of paclitaxel proteinbound particles for injectable suspension (albumin-bound) therapy. 5.6 Use in Patients with Hepatic Impairment

The exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment. Closely monitor patients with hepatic impairment for severe myelosuppression Paclitaxel protein-bound particles for injectable suspension (albumin-

bound) is not recommended in patients who have total bilirubin >5 x ULN or AST >10 x ULN. In addition, paclitaxel proteinbound particles for injectable suspension (albumin-bound) is not recommended in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST \leq 10 x ULN). Reduce the starting dose for patients with moderate or severe hepatic impairment [see Dosage and Administration (2.5), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. 7 Albumin (Human)

Paclitaxel protein-bound particles for injectable suspension (albuminbound) contains albumin (human), a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries a remote risk for transmission of viral diseases A theoretical risk for transmission of Creutzfeldt-Jakob Disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin. 8 Embryo-Fetal Toxicity


Based on mechanism of action and findings in animals, paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to rats during pregnancy at doses lower than the maximum recommended human dose, based on body surface area, caused embryo-fetal toxicities,


including intrauterine mortality, increased resorptions, reduced numbers of live fetuses, and malformations. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with paclitaxel protein-bound particles for injectable suspension

(albumin-bound) and for at least six months after the last dose of bound) [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)].


Complete packaging individual solutions**	NOSCO GRAPHIC SERVICES 11200 88th Avenue, Pleasant Prairie, WI 53158 I Phone: 847.336.4200 Serving Nosco Facilities in Illinois, Texas, Pennsylvania and New York.	Proof B 1/19/2022
Product Information	Specified Colors	Approved By
Item: 112455 Eval: X5082623 Cust: CELGENE Size: +39. x +20.5 Folded Size: 3.75 x 1.8125	Black	Name Date OK to Print New Proof Required We must have signed proof before we can begin production.
	H)H) Head to Head	This proof is to show size, copy placement and color break. Spot/PMS colors will be matched on press to: PMS Book, 4 Color Process Digital Color Guide, Extended Gamut Digital Color Guide and/or approved color standards. 4 Color Process proofs are verified to G7 standards and approved for color match.

PDF/X When correctly rendered in compliance with PDF/X standards no 'x' should appear in any box Please check overprint settings should you see an 'x'





Bone Marrow



Fluid Retention/Edema y Symptoms Severe Symptoms strointestinal Any Symptoms Severe Symptoms^c ny Symptoms evere Symptoms^o

Any Symptom

Any Symptoms

Alopecia

vere Symptoms

Severe Symptoms[°]

lepatic (Patients with Norma

Bilirubin Elevation Alkaline Phosphatase Ele ST (SGOT) Elevations Injection Site Reaction Paclitaxel injection patients received premedicatio Includes treatment-related events related to hypersensitivity (e.g., flushing, o bain, hypotension) that began on a day of dosing. Severe events are defined as at least Grade 3 toxicity

ment of metastatic breast cancer.

Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least three months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Use in Specific

Because clinical trials are conducted under widely varving conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (≥ 20%) with single-agent use of

aclitaxel protein-bound particles for injectable suspension (albumin bound) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/ arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea [see Adverse Reactions (6.1)]. The most common adverse reactions ($\geq 20\%$) of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with carboplatin for non-small cell lung cancer are anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue [see Adverse Reactions (6.1)]. The most common serious adverse reactions of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with carboplatin for non-small cell lung cancer are anemia (4%) and pneumonia (3%). The most common adverse reactions resulting

in permanent discontinuation of paclitaxel protein-bound particles for injectable suspension (albumin-bound) are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%). he most common adverse reactions resulting in dose reduction of paclitaxel protein-bound particles for injectable suspension albumin-bound) are neutropenia (24%), thrombocytopenia (13%) and anemia (6%). The most common adverse reactions leading to withholding or delay in paclitaxel protein-bound particles for injectable suspension (albumin-bound) dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%). In a randomized open-label trial of paclitaxel protein-bound particles

for injectable suspension (albumin-bound) in combination with gencitabine for pancreatic adenocarcinoma (see Clinical Studies (14.3), the most common ($\geq 20\%$) selected (with a $\geq 5\%$ higher ncidence) adverse reactions of paclitaxel protein-bound particles for injectable suspension (albumin-bound) are neutropenia, fatique, peripheral neuropathy, nausea, alopecia, peripheral edema, dia rhea, pyrexia, vomiting, decreased appetite, rash, and dehydration [see Adverse Reactions (6,1)]. The most common serious adverse reactions of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (with a $\geq 1\%$ higher incidence) are pyrexia (6%), dehydration (5%), pneumonia (4%, and vomiting (4%). The most common adverse reactions resulting in permanent discontinuation of paclitaxel protein-bound particles for injectable suspension (albumin-bound) are peripheral neuropathy (8%), fatigue (4%), and thrombocytopenia (2%). The most common adverse reactions resulting in dose reduction of paclitaxel protein-bound particles for injectable suspension (albumin-bound) are neutropenia (10%) and

peripheral neuropathy (6%). The most common adverse reactions eading to withholding or delay in paclitaxel protein-bound particles for injectable suspension (albumin-bound) dosing are neutropenia (16%), thrombocytopenia (12%), fatigue (8%), peripheral neurop-

able 6 shows the frequency of important adverse reactions in the randomized comparative trial for the patients who received either single-agent paclitaxel protein-bound particles for injectable suspension (albumin-bound) or paclitaxel injection for the treat-

able 6: Adverse Reactions in the Randomized Metastatic Breast Cancer Study on an Every-3-Weeks Schedule Percent of Patients Paclitaxel protein-bound particles for injectable Paclitaxel Injection

ticles for injectable nsion (albumin-bound) mg/m² over 30 min (n=229)	Paclitaxel Injection 175 mg/m² over 3 hª (n=225)
80 9	82 22
2 <1	3 <1
33 1	25 <1
24	20
2	1
<1	<1
2	2
4	12
0	2
<1	<1
5	5
3	4
60	52
35	30
7	6
12	9
71	56
10	2
44	49
8	49
0	4
47	39
8	3
10	8
0	<1
30	22
3	<1
-	
18	10
4	1
27	15
<1	1
7	6
7	6

Other Adverse Reactions lematologic Disorders

Neutropenia was dose dependent and reversible. Among patients with metastatic breast cancer in the randomized trial, neutrophil counts declined below 500 cells/mm³ (Grade 4) in 9% of the patients treated with a dose of 260 mg/m² compared to 22% in patients receiving paclitaxel injection at a dose of 175 mg/m². Pancytopenia has been observed in clinical trials.

Infectious episodes were reported in 24% of the patients treated with paclitaxel protein-bound particles for injectable suspension (albuminbound). Oral candidiasis, respiratory tract infections and pneumonia were the most frequently reported infectious complications. Hypersensitivity Reactions (HSRs) Grade 1 or 2 HSRs occurred on the day of paclitaxel protein-bound

particles for injectable suspension (albumin-bound) administration and consisted of dyspnea (1%) and flushing, hypotension, chest pain, and arrhythmia (all <1%). The use of paclitaxel proteinbound particles for injectable suspension (albumin-bound) in patients previously exhibiting hypersensitivity to paclitaxel injection or human albumin has not been studied. Cardiovascular

Hypotension, during the 30-minute infusion, occurred in 5% of patients. Bradycardia, during the 30-minute infusion, occurred in <1% of patients. These vital sign changes most often caused no symptoms and required neither specific therapy nor treatment

Severe cardiovascular events possibly related to single-agent paclitaxel protein-bound particles for injectable suspensi albumin-bound) occurred in approximately 3% of patients. These events included cardiac ischemia/infarction, chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension Cases of cerebrovascular attacks (strokes) and transient ischemic attacks have been reported.

Electrocardiogram (ECG) abnormalities were common among patients at baseline. ECG abnormalities on study did not usually result in symptoms, were not dose-limiting, and required no intervention, ECG abnormalities were noted in 60% of patients Among patients with a normal ECG prior to study entry, 35% of all patients developed an abnormal tracing while on study. The most requently reported ECG modifications were non-specific repolarization onormalities, sinus bradycardia, and sinus tachycardia.

Dyspnea (12%), cough (7%), and pneumothorax (<1%) were reported after treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound)

The frequency and severity of sensory neuropathy increased with cumulative dose. Sensory neuropathy was the cause of paclitaxel protein-bound particles for injectable suspension (albumin-bound) discontinuation in 7/229 (3%) patients. Twenty-four patients (10%) treated with paclitaxel protein-bound particles for injectable suspension (albumin-bound) developed Grade 3 peripheral neuropathy: of these patients, 14 had documented improvement after a median of 22 days. 10 patients resumed treatment at a reduced dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) and 2 discontinued due to peripheral neuropathy. Of the 10 patients without documented improvement, 4 discontinued the study due to peripheral neuropathy. No Grade 4 sensory neuropathies were reported. Only one inci-

dent of motor neuropathy (Grade 2) was observed in either arm of the controlled trial. Vision Disorders Ocular/visual disturbances occurred in 13% of all patients (n=366)treated with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and 1% were severe. The severe cases (keratitis and blurred vision) were reported in patients who received

higher doses than those recommended (300 or 375 mg/m²). These effects generally have been reversible. Arthralaia/Mvalaia

The symptoms were usually transient, occurred two or three days after paclitaxel protein-bound particles for injectable suspension (albumin-bound) administration, and resolved within a few days Grade 3 or 4 elevations in GGT were reported for 14% of patients

treated with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and 10% of patients treated with paclitaxel injection in the randomized trial.

Overall 11% of patients experienced creatinine elevation, 1% severe. No discontinuations, dose reductions, or dose delays were caused by renal toxicities. Other Clinical Events

Nail changes (changes in pigmentation or discoloration of nail bed) have been reported. Edema occurred in 10% of patients: no patients had severe edema. Dehydration and pyrexia were also reported.

Non-Small Cell Lung Cancer Adverse reactions were assessed in 514 paclitaxel protein-bound particles for injectable suspension (albumin-bound)/carboplatin treated patients and 524 paclitaxel injection/carboplatin-treated patients receiving first-line systemic treatment for locally advanced (stage IIIB) or metastatic (IV) non-small cell lung cancer (NSCLC) in a multicenter, randomized, open-label trial, Paclitaxel proteinbound particles for injectable suspension (albumin-bound) wa administered as an intravenous infusion over 30 minutes at a dose of 100 mg/m² on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as an intravenous infusion over 3 hours at a dose of 200 mg/m², following premedication. In both treatment arms carboplatin at a dose of AUC = 6 mg·min/mL was administered intravenously on Day 1 of each 21-day cycle after completion of paclitaxel protein-bound particles for injectable suspension (albumin-bound)/paclitaxel infusion.

The differences in paclitaxel dose and schedule between the two arms limit direct comparison of dose- and schedule-dependent adverse reactions. Among patients evaluable for adverse reactions, the median age was 60 years, 75% were men, 81% were White, 49% had adenocarcinoma, 43% had squamous cell lung cancer, 76% were ECOG PS 1. Patients in both treatment arms received a median of 6 cycles of treatment.

The following common (\geq 10% incidence) adverse reactions were observed at a similar incidence in paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus carboplatin-treated and paclitaxel injection plus carboplatin-treated patients: alopecia 56%, nausea 27%, fatigue 25%, decreased appetite 17%, asthenia 16%, constipation 16%, diarrhea 15% vomiting 12%, dyspnea 12%, and rash 10% (incidence rates are

for the paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus carboplatin treatment group). Table 7 provides the frequency and severity of laboratory-detected abnormalities which occurred with a difference of \geq 5% for al grades (1-4) or $\geq 2\%$ for Grade 3-4 toxicity between paclitaxel protein-bound particles for injectable suspension (albumin-bound)

plus carboplatin-treated patients or paclitaxel injection plus arboplatin-treated patients. Table 7: Selected Hematologic Laboratory-Detected

Abnormalities with a Difference of \geq 5% for grades (1-4) or ≥ 2% for Grade 3-4 Toxicity Between Treatment Groups

6							
0 94		Paclitaxel protein-b injectable suspensio (100 mg/m² weekly	n (albumin-bound)	(200 mg/	el Injection m ² every 3 s carboplatin		
		Grades 1-4 (%)	Grade 3-4 (%)	Grades 1-4 (%)	Grade 3-4 (%)		
7 31	Anemia ^{1,2}	98	28	91	7		
32	Neutropenia ^{1,3}	85	47	83	58		
1	Thrombocytopenia ^{1,3}	68	18	55	9		
dyspnea, chest			/carboplatin-treated g	group.	le suspension		

Table 8 provides the frequency and severity of adverse reactions. which occurred with a difference of \geq 5% for all grades (1-4) or \geq % for Grade 3-4 between either treatment group for the 514 pack taxel protein-bound particles for injectable suspension (albumin bound) plus carboplatin-treated patients compared with the 524 patients who received paclitaxel injection plus carboplatin. Table 8: Selected Adverse Reactions with a Difference of \geq 5% for All Grade Toxicity or \geq 2% for Grade 3-4 Toxicity

Between Treatment Groups

		Paclitaxel pr particles for suspension bound) (1 weekly) + (N=	Paclitaxel Injection (200 mg/m ² every 3 weeks) + carboplatin (N=524)		
System Organ Class	Adverse Reaction	Grade 1-4 Toxicity (%)	Grade 3-4 Toxicity (%)	Grades 1-4 Toxicity (%)	Grade 3-4 Toxicity (%)
Nervous system disorders	Peripheral neuropathy ^a	48	3	64	12
General disorders and administration site conditions	Edema peripheral	10	0	4	<1
Respiratory thoracic and mediastinal disorders	Epistaxis	7	0	2	0
Musculoskeletal and connective	Arthralgia	13	<1	25	2
tissue disorders	Myalgia	10	<1	19	2

For the paclitaxel protein-bound particles for injectable suspen sion (albumin-bound) plus carboplatin treated group, 17/514 (3%) patients developed Grade 3 peripheral neuropathy and no patients developed Grade 4 peripheral neuropathy. Grade 3 neuropathy improved to Grade 1 or resolved in 10/17 patients (59%) following

interruption or discontinuation of paclitaxel protein-bound particles for injectable suspension (albumin-bound). Adenocarcinoma of the Pancreas

Adverse reactions were assessed in 421 patients who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus gemcitabine and 402 patients who received gemcitabine for the first-line systemic treatment of metastatic adenocarcinoma of the pancreas in a multicenter, multinaional, randomized, controlled, open-label trial, Patients received a median treatment duration of 3.9 months in the paclitaxel protein-bound particles for injectable suspension (albumin-bound) remeitabine group and 2.8 months in the gemeitabine group For the treated population, the median relative dose intensity for gemcitabine was 75% in the paclitaxel protein-bound particles niectable suspension (albumin-bound)/gemcitabine group and 85% in the gemcitabine group. The median relative dose intensity of paclitaxel protein-bound particles for injectable suspension albumin-bound) was 81%.

Table 9 provides the frequency and severity of laboratory-detected abnormalities which occurred at a higher incidence for Grades 1-4 ≥ 5%) or for Grade 3-4 (≥ 2%) toxicity in paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus gemcitabine-treated patients

Table 9: Selected Hematologic Laboratory-Detected Abnormalities with a Higher Incidence (\geq 5% for Grades 1-4 or \geq 2% for Grades 3-4 Events) in the paclitaxel protein-bound particles for injectable suspension (albumin-bound)/Gemcitabine Arm

	particles for suspension (a	rotein-bound or injectable Ibumin-bound) 'Gemcitabine ^d	Gemcitabine			
	Grades 1-4 (%)	Grade 3-4 (%)	Grades 1-4 Grade 3 (%) (%)			
Neutropenia ^{a,b}	73	38	58 27			
Thrombocytopenia ^{b,c}	74	13	70	9		
^a 405 patients assessed in paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine-treated group.						

^b 388 patients assessed in gemcitabine-treated group. patients assessed in paclitaxel protein-bound particles for injectable suspension utrophil growth factors were administered to 26% of patients in the paclitaxel proteinbound particles for injectable suspension (albumin-bound)/gemcitabine group.

Table 10 provides the frequency and severity of adverse reactions which occurred with a difference of $\geq 5\%$ for all grades or $\geq 2\%$ for Grade 3 or higher in the paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus gemcitabine-treated group compared to the gemcitabine group. Table 10: Selected Adverse Reactions with a Higher

Incidence (\geq 5% for All Grade Toxicity or \geq 2% for Grade 3 or Higher Toxicity) in the paclitaxel protein-bound particles fo injectable suspension (albumin-bound)/Gemcitabine Arm

		Paclitaxel protein- bound particles for injectable suspension (albumin-bound) (125 mg/m ²) and gemcitablne (N=421)		Gemcitabine (N=402)	
System Organ Class	Adverse Reaction	All Grades	Grade 3 or Higher	All Grades	Grade 3 or Higher
General disorders and administration	Fatigue	248 (59%)	77 (18%)	183 (46%)	37 (9%)
site conditions	Peripheral edema	194 (46%)	13 (3%)	122 (30%)	12 (3%)
	Pyrexia	171 (41%)	12 (3%)	114 (28%)	4 (1%)
	Asthenia	79 (19%)	29 (7%)	54 (13%)	17 (4%)
	Mucositis	42 (10%)	6 (1%)	16 (4%)	1 (<1%)
Gastrointestinal disorders	Nausea	228 (54%)	27 (6%)	192 (48%)	14 (3%)
usolueis	Diarrhea	184 (44%)	26 (6%)	95 (24%)	6 (1%)
	Vomiting	151 (36%)	25 (6%)	113 (28%)	15 (4%)
Skin and subcutaneous tissue	Alopecia	212 (50%)	6 (1%)	21 (5%)	0
disorders	Rash	128 (30%)	8 (2%)	45 (11%)	2 (<1%)
Nervous system disorders	Peripheral neuropathy ^a	227 (54%)	70 (17%)	51 (13%)	3 (1%)
	Dysgeusia	68 (16%)	0	33 (8%)	0
	Headache	60 (14%)	1 (<1%)	38 (9%)	1 (<1%)
Metabolism and nutrition disorders	Decreased appetite	152 (36%)	23 (5%)	104 (26%)	8 (2%)
	Dehydration	87 (21%)	31 (7%)	45 (11%)	10 (2%)
	Hypokalemia	52 (12%)	18 (4%)	28 (7%)	6 (1%)
Respiratory, thoracic and mediastinal	Cough	72 (17%)	0	30 (7%)	0
disorders	Epistaxis	64 (15%)	1 (<1%)	14 (3%)	1 (<1%)
Infections and infestations	Urinary tract infections ^b	47 (11%)	10 (2%)	20 (5%)	1 (<1%)
Musculoskeletal and connective tissue	Pain in extremity	48 (11%)	3 (1%)	24 (6%)	3 (1%)
disorders	Arthralgia	47 (11%)	3 (1%)	13 (3%)	1 (<1%)
	Myalgia	44 (10%)	4 (1%)	15 (4%)	0
Psychiatric disorders	Depression	51 (12%)	1 (<1%)	24 (6%)	0

Jrinary tract infections includes the preferred terms of: urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, and urinary tract infection enterococca Additional clinically relevant adverse reactions that were reported in < 10% of the patients with adenocarcinoma of the pancreas who received paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine included: Infections & infestations: oral candidiasis, pneumonia Vascular disorders: hypertension Cardiac disorders: tachycardia, congestive cardiac failure Eye disorders: cystoid macular edema Peripheral Neuropathy

Grade 3 peripheral neuropathy occurred in 17% of patients who received paclitaxel protein-bound particles for injectable suspen sion (albumin-bound)/gemcitabine compared to 1% of patients who received gemcitabine only: no patients developed Grade 4 peripheral neuropathy. The median time to first occurrence of Grade 3 peripheral neuropathy in the paclitaxel protein-bound parti cles for injectable suspension (albumin-bound) arm was 140 days Upon suspension of paclitaxel protein-bound particles for inject able suspension (albumin-bound) dosing the median time to improvement from Grade 3 peripheral neuropathy to \leq Grade was 29 days. Of paclitaxel protein-bound particles for injectable suspension (albumin-bound)-treated patients with Grade 3 periph eral neuropathy, 44% resumed paclitaxel protein-bound particles for injectable suspension (albumin-bound) at a reduced dose.

Sepsis occurred in 5% of patients who received paclitaxel proteinbound particles for injectable suspension (albumin-bound)/ gemcitabine compared to 2% of patients who received gemcit abine alone. Sepsis occurred both in patients with and without neutropenia. Risk factors for sepsis included biliary obstruction or presence of biliary stent.

Pneumonitis occurred in 4% of patients who received paclitaxel protein-bound particles for injectable suspension (albuminbound)/gemcitabine compared to 1% of patients who received gemcitabine alone. Two of 17 patients in the paclitaxel proteinbound particles for injectable suspension (albumin-bound) arm with pneumonitis died.

Postmarketing Experience The following adverse reactions have been identified during postapproval use of paclitaxel protein-bound particles for inject able suspension (albumin-bound) or with paclitaxel injection and may be expected to occur with paclitaxel protein-bound particles for injectable suspension (albumin-bound). Because these reac tions are reported voluntarily from a population of uncertain size. it is not always possible to reliably estimate their frequency or

establish a causal relationship to drug exposure. Hypersensitivity Reactions Severe and sometimes fatal hypersensitivity reactions. Crosshypersensitivity between paclitaxel protein-bound particles for injectable suspension (albumin-bound) and other taxanes has been reported.

Cardiovascula concestive heart failure. left ventricular dysfunction, and atrioventricular block. Most patients were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac Respirato

Pneumonitis, interstitial pneumonia, and pulmonary embolism Radiation pneumonitis in patients receiving concurrent radiotherapy. Lung fibrosis has been reported with paclitaxel injection.

Cranial nerve palsies and vocal cord paresis, as well as autonomic neuropathy resulting in paralytic ileus. Vision Disorders

Reduced visual acuity due to cystoid macular edema (CME). After cessation of treatment, CME may improve, and visual acuity may return to baseline. Abnormal visual evoked potentials in patients treated with paclitaxel injection suggest persistent optic nerve damage.

Hepatic necrosis and hepatic encephalopathy leading to death in patients treated with paclitaxel injection. Gastrointestinal (GI) Intestinal obstruction, intestinal perforation, pancreatitis, and

ischemic colitis. In patients treated with paclitaxel injection. neutropenic enterocolitis (typhlitis) despite the coadministration of G-CSF, alone and in combination with other chemotherapeutic Injection Site Reaction

Extravasation. Closely monitor the paclitaxel protein-bound particles for injectable suspension (albumin-bound) infusion site for possible infiltration during drug administration [see Dosage and Administration 2.1) Severe events such as phlebitis, cellulitis, induration, necrosis,

and fibrosis have been reported with paclitaxel injection. In some cases, the onset of the injection site reaction occurred during a prolonged infusion or was delayed up to ten days. Recurrence of skin reactions at a site of previous extravasation following administration of paclitaxel injection at a different site has been reported. Metabolic and Nutritional Disorders

Tumor lysis syndrome Other Clinical Events

Skin reactions including generalized or maculopapular rash, vthema, and pi Photosensitivity reactions, radiation recall phenomenon, sclero derma, and in some patients previously exposed to capecitabine

reports of palmar-plantar erythrodysesthesia. Stevens-Johnsor syndrome and toxic epidermal necrolysis have been reported Conjunctivitis, cellulitis, and increased lacrimation have been reported with paclitaxel injection. Accidental Exposure

Upon inhalation of paclitaxel, dyspnea, chest pain, burning eyes, sore throat, and nausea have been reported. Following topical exposure, tingling, burning, and redness have been reported.

7 DRUG INTERACTIONS The metabolism of paclitaxel is catalyzed by CYP2C8 and CYP3A4. Caution should be exercised when administering pac itaxel protein-bound particles for injectable suspension (albuminbound) concomitantly with medicines known to inhibit or induce either CYP2C8 or CYP3A4.

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy

Risk Summary Based on its mechanism of action and findings in animals, paclitaxel protein-bound particles for injectable suspension (albumin bound) can cause fetal harm when administered to a pregnan woman [see Clinical Pharmacology (12.1)]. There are no available human data on paclitaxel protein-bound particles for injectable

suspension (albumin-bound) use in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of paclitaxel formulated as albumin-bound particles to pregnant rats during the period of organogenesis resulted in embryo-fetal toxicity at doses approximately 2% of the daily maximum recommended human dose on a mg/m² basis (see Data). Advise females of reproductive

potential of the potential risk to a fetus. The background rate of major birth defects and miscarriage is unknown for the indicated population. In the U.S. general popu lation, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and

15% to 20%, respectively.

Animal Data

In embryo-fetal development studies, intravenous administra tion of paclitaxel formulated as albumin-bound particles to rats during pregnancy, on gestation days 7 to 17 at doses of 6 mg/m²

all over your body.
throat, or trouble swallowing, hives (raised bumps), rash, or redness
swelling of your face, lips, tongue,
reaction: trouble breathing, sudden
of these signs of a serious allergic
provider right away if you get any
bound). Tell your healthcare
for injectable suspension (albumin-
paclitaxel protein-bound particles
eactions during your infusion of
will monitor you closely for allergic
cines. Your healthcare provider
are allergic to other taxane medi-
suspension (albumin-bound) if you
bound particles for injectable
eaction to paclitaxel protein-
increased risk of having an allergic
can lead to death. You may have an
suspension (albumin-bound) and
protein-bound particles for injectable

(approximately 2% of the daily maximum recommended human dose on a mg/m² basis) caused embryo-fetal toxicities, as indicated by intrauterine mortality, increased resorptions (up to 5-fold) reduced numbers of litters and live fetuses, reduction in fetal body weight, and increase in fetal anomalies. Fetal anomalies included soft tissue and skeletal malformations, such as eve bulge, folded retina, microphthalmia, and dilation of brain ventricles. 8.2 Lactation

<u>Risk Summary</u> There are no data on the presence of paclitaxel in human milk. or its effect on the breastfed child or on milk production. In animal studies, paclitaxel and/or its metabolites were excreted into the milk of lactating rats (see Data). Because of the potential for serious adverse reactions in a breastfed child from paclitaxel proteinbound particles for injectable suspension (albumin-bound), advise lactating women not to breastfeed during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for two weeks after the last dose.

Animal Data Following intravenous administration of radiolabeled paclitaxel to rats on days 9 to 10 postpartum, concentrations of radioactivity in milk were higher than in plasma and declined in parallel with the plasma concentrations.

8.3 Females and Males of Reproductive Potential Based on animal studies and mechanism of action, paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to starting treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound). Contraception

Advise females of reproductive potential to use effective contraception and avoid becoming pregnant during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least six months after the last dose of paclitaxel proteinbound particles for injectable suspension (albumin-bound).

Based on findings in genetic toxicity and animal reproduction studies, advise males with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least three months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)].

Females and Males Based on findings in animals, paclitaxel protein-bound particles for injectable suspension (albumin-bound) may impair fertility in females and males of reproductive potential *[see Nonclinical Toxi*cology (13.1)].

8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Pharmacokinetics, safety, and antitumor activity of paclitaxel protein-bound particles for injectable suspension (albumin-bound) were assessed in an open-label, dose escalation, dose expansion study (NCT01962103) in 96 pediatric patients aged 1.4 to < 17 years with recurrent or refractory pediatric solid tumors. The maximum tolerated dose (MTD) normalized for body surface area (BSA) was lower in pediatric patients compared to adults. No new safety signals were observed in pediatric patients across these studies.

Paclitaxel protein-bound exposures normalized by dose were higher in 96 pediatric patients (aged 1.4 to < 17 years) as compared to those in adults. 8.5 Geriatric Use

Of the 229 patients in the randomized study who received paclitaxel protein-bound particles for injectable suspension (albuminound) for the treatment of metastatic breast cancer, 13% were at least 65 years of age and < 2% were 75 years or older. This study of paclitaxel protein-bound particles for injectable suspension (albumin-bound) did not include a sufficient number of patients with metastatic breast cancer who were 65 years and older to determine whether they respond differently from younger patients. A subsequent pooled analysis was conducted in 981 patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound) monotherapy for metastatic breast cancer, of which 15% were 65 years of age or older and 2% were 75 years of age or older. A higher incidence of epistaxis, diarrhea, dehydration, fatigue, and peripheral edema was found in patients 65 years

of age or older.

Of the 514 patients in the randomized study who received paclitaxel protein-bound particles for injectable suspension (albuminbound) and carboplatin for the first-line treatment of non-small cell lung cancer. 31% were 65 years or older and 3.5% were 75 years or older. Myelosuppression, peripheral neuropathy, and arthralgia were more frequent in patients 65 years or older compared to patients younger than 65 years old. No overall difference in effecpatients 65 years or older compared to patients younger than 65 vears old.

Of the 431 patients in the randomized study who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine for the first-line treatment of pancreatic adenocarcinoma, 41% were 65 years or older and 10% were 75 years or older. No overall differences in effectiveness were observed between patients who were 65 years of age or older and younger patients. Diarrhea, decreased appetite, dehydration, and epistaxis were more frequent in patients 65 years or older compared with patients younger than 65 years old. Clinical studies of paclitaxel protein-bound particles for injectable suspension (albumin-bound) did not include sufficient number of patients with pancreatic cancer who were 75 years and older to determine whether they respond differently from younger patients.

8.6 Renal Impairment No adjustment of the starting paclitaxel protein-bound particles for injectable suspension (albumin-bound) dose is required for patients with mild to moderate renal impairment (estimated creatinine clearance 30 to <90 mL/min) [see Clinical Pharmacology (12.3)]. There are insufficient data to permit dosage recommenda tions in patients with severe renal impairment or end stage renal disease (estimated creatinine clearance <30 mL/min). 8.7 Hepatic Impairment

No adjustment of the starting paclitaxel protein-bound particles for injectable suspension (albumin-bound) dose is required for patients with mild hepatic impairment (total bilirubin > ULN and \leq 1.5 x ULN and aspartate aminotransferase [AST] \leq 10 x ULN). Reduce paclitaxel protein-bound particles for injectable suspension (albumin-bound) starting dose in patients with moderate to severe hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is not recommended for use in patients with total bilirubin $> 5 \times ULN$ or AST > 10 x ULN [see Dosage and Administration (2.5), Warnings and Precautions (5.6), and Clinical Pharmacology (12.3)]. Paclitaxel protein-bound particles for injectable suspension (albumin-bound is not recommended for use in patients with metastatic adenocarcinoma of the pancreas who have moderate to severe hepatic impairment [see Dosage and Administration (2.5)].

10 OVERDOSAGE There is no known antidote for paclitaxel protein-bound particles for injectable suspension (albumin-bound) overdosage. The primary anticipated complications of overdosage would consist of bone marrow suppression, sensory neurotoxicity, and mucositis.

DESCRIPTION Paclitaxel protein-bound particles for injectable suspension

(albumin-bound) is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers. Paclitaxel exists in the particles in a non-crystalline, amorphous state. Paclitaxel is a microtubule inhibitor. The chemical name for paclitaxel is 5β ,20-Epoxy-1,2 α ,4,7 β ,10 β ,13 α hexahvdroxvtax-11-en-9-one 4.10-diacetate 2-benzoate 13-ester with (2R.3S)-N-benzovI-3-phenylisoserine. The empirical formula is $C_{47}H_{51}NO_{14}$ and the molecular weight is 853.91. Paclitaxel has the following structural formula:

Paclitaxel is a white to off-white crystalline powder. It is highly lipophilic, insoluble in water, and melts at approximately 216°C to

Paclitaxel protein-bound particles for injectable suspension (albuminbound) is supplied as a white to yellow, sterile, lyophilized powder for reconstitution with 20 mL of 0.9% Sodium Chloride Injection. USP prior to intravenous infusion. Each single-dose vial contains 100 mg of paclitaxel (bound to human albumin) and approximately 900 mg of human albumin (containing sodium caprylate and sodium acetyltryptophanate). Each milliliter (mL) of reconstituted suspension contains 5 mg paclitaxel formulated as albumin-bound particles. Paclitaxel protein-bound particles for

injectable suspension (albumin-bound) is free of solvents.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action

Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or "bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. 2.3 Pharmacokinetics

The pharmacokinetics of total paclitaxel following 30- and 180-minute infusions of paclitaxel protein-bound particles for injectable suspension (albumin-bound) at dose levels of 80 to 375 mg/m² (0.31 to 1.15 times the maximum approved recommended dosage) were determined in clinical studies. Dose levels of mg/m² refer to mg of paclitaxel in paclitaxel protein-bound particles for injectable suspension (albumin-bound). Following intravenous administration of paclitaxel protein-bound particles for injectable suspension (albumin-bound) to patients with solid tumors, paclitaxel plasma concentrations declined in a biphasic manner, the initial rapid decline representing distribution to the peripheral compartment and the slower second phase representing drug elimination.

Following paclitaxel protein-bound particles for injectable suspension (albumin-bound) infusion, paclitaxel exhibited linear drug exposure (AUC) across clinical doses ranging from 80 to 300 mg/m² (0.31 to 1.15 times the maximum approved recommended dosage). The pharmacokinetics of paclitaxel in paclitaxel proteinbound particles for injectable suspension (albumin-bound) were independent of the duration of intravenous administration. The pharmacokinetic data of 260 mg/m² paclitaxel protein-bound

particles for injectable suspension (albumin-bound) administered over a 30-minute infusion was compared to the pharmacokinetics of 175 mg/m² paclitaxel injection over a 3-hour infusion. Clearance was larger (43%) and the volume of distribution was higher (53%) for paclitaxel protein-bound particles for injectable suspension (albumin-bound) than for paclitaxel injection. There were no differences in terminal half-lives.

Following paclitaxel protein-bound particles for injectable suspension (albumin-bound) administration to patients with solid tumors. paclitaxel is evenly distributed into blood cells and plasma and is ahly bound to plasma proteins (94%). The total volume of distri bution is approximately 1741 L; the large volume of distribution indicates extensive extravascular distribution and/or tissue binding of paclitaxel

In a within-patient comparison study, the fraction of unbound paclitaxel in plasma was significantly higher with paclitaxel proteinbound particles for injectable suspension (albumin-bound) (6.2%) than with solvent-based paclitaxel (2.3%). This contributes to significantly higher exposure to unbound paclitaxel with paclitaxel protein-bound particles for injectable suspension (albumin-bound) compared with solvent-based paclitaxel, when the total exposure is comparable. In vitro studies of binding to human serum proteins, using paclitaxel concentrations ranging from 0.1 to 50 μ g/mL, indicated that the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.

At the clinical dose range of 80 to 300 mg/m² (0.31 to 1.15 times the maximum approved recommended dosage), the mean total clearance of paclitaxel ranges from 13 to 30 L/h/m² and the mean terminal half-life ranges from 13 to 27 hours.

Metabolism

Specific Populations

AST $\leq 10 \times ULN$).

In vitro studies with human liver microsomes and tissue slices showed that paclitaxel in paclitaxel protein-bound particles for injectable suspension (albumin-bound) was metabolized primarily to 6α -hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'-p-hydroxypaclitaxel and 6α , 3'-p-dihydroxypaclitaxel, by CYP3A4. In vitro, the metabolism of paclitaxel to 6α -hydroxypaclitaxel was inhibited by a number of agents (ketoconazole, verapamil, diazepam, quinidine, dexamethasone, cyclosporin, teniposide, etoposide, and vincristine), but the concentrations used exceeded those found in vivo following normal therapeutic doses. Testosterone, 17α -ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6α -hydroxypaclitaxel in vitro. The pharmacokinetics of paclitaxel may also be altered in vivo as a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and/or CYP3A4 [see Drug Interactions (7)] Excretior

After a 30-minute infusion of 260 mg/m² doses of paclitaxel proteinbound particles for injectable suspension (albumin-bound), the mean values for cumulative urinary recovery of unchanged drug (4%) indicated extensive non-renal clearance. Less than 1% of the total administered dose was excreted in urine as the metabolites 6α -hydroxypaclitaxel and 3'-p-hydroxypaclitaxel. Fecal excretion was approximately 20% of the total dose administered.

No clinically meaningful differences in the pharmacokinetics of paclitaxel in paclitaxel protein-bound particles for injectable suspension (albumin-bound) were observed based on body weight (40 to 143 kg), body surface area (1.3 to 2.4 m²), sex, race (Asian vs. White), age (24 to 85 years), type of solid tumors, mild to moderate renal impairment (creatinine clearance 30 to <90 mL/min), and mild hepatic impairment (total bilirubin >1 to \leq 1.5 x ULN and

Patients with moderate (total bilirubin >1.5 to 3 x ULN and AST \leq 10 x ULN) or severe (total bilirubin >3 to 5 x ULN) hepatic impairment had a 22% to 26% decrease in the maximum elimination rate of paclitaxel and approximately 20% increase in mean paclitaxel AUC compared with patients with normal hepatic function (total bilirubin SULN and AST SULN [see Dosage and Administration (2.5) and Use in Specific Populations (8.7)].

The effect of severe renal impairment or end stage renal disease (creatinine clearance < 30 mL/min) on the pharmacokinetics of paclitaxel in paclitaxel protein-bound particles for injectable suspension (albumin-bound) is unknown. Drug Interaction Studies Carboplatin: Administration of carboplatin immediately after the

completion of the paclitaxel protein-bound particles for injectable suspension (albumin-bound) infusion to patients with NSCLC did not cause clinically meaningful changes in paclitaxel exposure. The observed mean AUC_{inf} of free carboplatin was approximately 23% higher than the targeted value (6 min*mg/mL), but its mean half-life and clearance were consistent with those reported in the absence of paclitaxel.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of paclitaxel protein-bound particles for

injectable suspension (albumin-bound) has not been studied. Paclitaxel was clastogenic in vitro (chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice). Paclitaxel was not mutagenic in the Ames test or the CHO/HGPRT gene mutation assay.

Administration of paclitaxel formulated as albumin-bound particles to male rats at 42 mg/m² on a weekly basis (approximately 16% of the daily maximum recommended human exposure on a body surface area basis) for 11 weeks prior to mating with untreated female rats resulted in significantly reduced fertility accompanied by decreased pregnancy rates and increased loss of embryos in mated females. A dose of 42 mg/m² also reduced male reproductive organ weights, mating performance, and sperm production. Testicular atrophy/degeneration was observed in single-dose toxicology studies in animals administered paclitaxel formulated as albumin-bound particles at doses lower than the recommended human dose: doses were 54 mg/m² in rodents and 175 mg/m² in

dogs. Similar testicular degeneration was seen in monkeys administered three weekly doses of 108 mg/m² paclitaxel formulated as albumin bound particles. Administration of paclitaxel prior to and during mating produced impairment of fertility in male and female rats. Paclitaxel caused reduced fertility and reproductive indices, and increased embryo-

14 CLINICAL STUDIES 14.1 Metastatic Breast Cancer

fetal toxicity.


Data from 106 patients accrued in two single arm open label studies and from 460 patients enrolled in a randomized comparative study were available to support the use of paclitaxel proteinbound particles for injectable suspension (albumin-bound) in metastatic breast cancer. Single Arm Open Label Studies

In one study, paclitaxel protein-bound particles for injectable suspension (albumin-bound) was administered as a 30-minute infusion at a dose of 175 mg/m² to 43 patients with metastatic breast cancer. The second trial utilized a dose of 300 mg/m² as a 30-minute infusion in 63 patients with metastatic breast cancer. Cycles were administered at 3-week intervals. Objective responses were observed in both studies.

Randomized Comparative Study This multicenter trial was conducted in 460 patients with metastatic breast cancer. Patients were randomized to receive paclitaxel protein-bound particles for injectable suspension (albumin-bound) at a dose of 260 mg/m² given as a 30-minute infusion, or paclitaxel injection at 175 mg/m² given as a 3-hour infusion. Sixty-four percent of patients had impaired performance status (ECOG 1 or 2) at study entry; 79% had visceral metastases; and 76% had > 3 sites of metastases. Fourteen percent of the patients had not received prior chemotherapy: 27% had received chemotherapy in the adjuvant setting, 40% in the metastatic setting and 19% in both metastatic and adjuvant settings. Fifty-nine percent received study drug as second or greater than second-line therapy. Seventyseven percent of the patients had been previously exposed to

anthracvclines In this trial, patients in the paclitaxel protein-bound particles for injectable suspension (albumin-bound) treatment arm had a statistically significantly higher reconciled target lesion response rate (the trial primary endpoint) of 21.5% (95% CI: 16.2% to 26.7%), compared to 11.1% (95% CI: 6.9% to 15.1%) for patients in the paclitaxel injection treatment arm. See Table 11. There was

no statistically significant difference in overall survival between the two study arms. Table 11: Efficacy Results from Randomized Metastatic Breast Cancer Trial



Acconciled larget Lesion Response rate (LLRH) was the prospectively demined protocol appoint endpoint, based on independent radiologic assessment of tumor responses reconciled with investigator responses (which also included clinical information) for the first 6 cycles of with investigator responses (which also included clinical information) for the first 6 cycles of therapy. The reconciled TLRR was lower than the investigator Reported Response Rates, hich are based on all cycles of therapy. from Cochran-Mantel-Haenszel test stratified by 1st line vs. > 1st line therapy. Prior therapy included an anthracycline unless clinically contraindicated

14.2 Non-Small Cell Lung Cancer A multicenter, randomized, open-label study was conducted in 1052 chemotherapy naive patients with Stage IIIb/IV non-small cell lung cancer to compare paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with carboplatin to paclitaxel injection in combination with carboplatin as first-line treatment in patients with advanced non-small cell lung cancer. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) was administered as an intravenous infusion over 30 minutes at a dose of 100 mg/m² on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as an intravenous infusion over 3 hours at a dose of 200 mg/m², following premedication. In both treatment arms carboplatin at a dose of AUC = 6 mg·min/mL was administered intravenously on Day 1 of each 21-day cycle after completion of paclitaxel protein-bound particles for injectable suspension (albumin-bound)/paclitaxel infusion. Treatment was administered until disease progression or development of an unacceptable toxicity. The major efficacy outcome measure was overall response rate as determined by a central independent review committee using RECIST guidelines In the intent-to-treat (all-randomized) population, the median age was 60 years, 75% were men, 81% were White, 49% had adenocarcinoma, 43% had squamous cell lung cancer, 76% were ECOG PS 1, and 73% were current or former smokers. Patients received a median of 6 cycles of treatment in both study arms. Patients in the paclitaxel protein-bound particles for injectable

(Version 1.0). suspension (albumin-bound)/carboplatin arm had a statistically significantly higher overall response rate compared to patients the paclitaxel injection/carboplatin arm [(33% versus 25%) see

survival between the two study arms.

Injection 175 mg/m²

12/143 (8.4%) [3.85% – 12.94%]

Table 12]. There was no statistically significant difference in overall

Cancer Trial (Intent-to-Treat Population) Paclitaxel protein-bound Paclitaxel Injection particles for injectable uspension (albumin-bound) (200 mg/m² every 3 weeks) (100 mg/m² weekly) + carboplátin (N=531) carboplat (N=521) Overall Response Rate (ORR) nfirmed complete 170 (33%) 132 (25%) or partial overall esponse. n (%) 95% CI 28.6. 36.7 21.2, 28.5 P-value 0.005 (Chi-Square test) 6.9 (5.6, 8.0) 6.0 (5.6, 7.1) months (95% Cl Overall Response Rate by Histology 71/264 (27%) 66/254 (26%) Adenocarcinoma uamous Cell 94/229 (41%) 54/221 (24%) 3/9 (33%) 2/13 (15%) Large Cell Carcinoma

Table 12: Efficacy Results from Randomized Non-Small Cell Lung

= confidence interval: DoB= Duration of response 14.3 Adenocarcinoma of the Pancreas

A multicenter, multinational, randomized, open-label study was conducted in 861 patients comparing paclitaxel protein-bound particles for injectable suspension (albumin-bound) plus gemcitabine versus gemcitabine monotherapy as first-line treatment of netastatic adenocarcinoma of the pancreas. Key eligibility criteria were Karnofsky Performance Status (KPS) \geq 70 normal bilirubin level, transaminase levels ≤ 2.5 times the upper limit of normal (ULN) or ≤ 5 times the ULN for patients with liver metastasis. no prior cytotoxic chemotherapy in the adjuvant setting or for etastatic disease, no ongoing active infection requiring systemi therapy, and no history of interstitial lung disease. Patients with rapid decline in KPS (≥10%) or serum albumin (≥20%) during the 14 day screening period prior to study randomization were ineliaible

7/29 (24%)

5/33 (15%)

A total of 861 patients were randomized (1:1) to the paclitaxel protein-bound particles for injectable suspension (albumin-bound)/ gemcitabine arm (N=431) or to the gemcitabine arm (N=430). Randomization was stratified by geographic region (Australia Western Europe, Eastern Europe, or North America), KPS (70 to 80 versus 90 to 100), and presence of liver metastasis (ves versus no). Patients randomized to paclitaxel protein-bound particles for injectable suspension (albumin-bound)/gemcitabine received paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m² as an intravenous infusion over 30-40 minutes followed by gemcitabine 1000 mg/m² as an intravenous infusion over 30-40 minutes on Days 1. 8. and 15 of each 28-day cycle. Patients randomized to gemcitabine received 1000 mg/m² as an intravenous infusion over 30-40 minutes weekly for 7 weeks followed by a 1-week rest period in Cycle 1 then as 1000 mg/m² on Days 1, 8, and 15 of each subsequent 28-day cycle. Patients in both arms received treatment until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall survival (OS). Additional outcome measures were

progression-free survival (PFS) and overall response rate (ORR), both assessed by independent, central, blinded radiological review using RECIST (version 1.0). In the intent-to-treat (all randomized) population, the median age was 63 years (range 27-88 years) with $42\% \ge 65$ years of age; 58% were men; 93% were White and KPS was 90-100 in 60%. Disease characteristics included 46% of patients with 3 or more metastatic sites; 84% of patients had liver metastasis; and the location of the primary pancreatic lesion was in the head of pancreas (43%), body (31%), or tail (25%).

Results for overall survival, progression-free survival, and overall response rate are shown in Table 13. Table 13: Efficacy Results from Randomized Study in Patients with Adenocarcinoma of the Pancreas (ITT Population)


	Paclitaxel protein-bound particles for injectable suspension (albumin- bound) (125 mg/m ²) and gemcitabine (N = 431)	Gemcitabine (N = 430)
Overall Survival		
lumber of deaths, n (%)	333 (77)	359 (83)
Median Overall Survival (months)	8.5	6.7
95% CI	7.9, 9.5	6.0, 7.2
HR (95% CI) ª	0.72 (0.62, 0.83)	
P-value ^b	<0.0001	
Progression-free Survival ^c		
eath or progression, n (%)	277 (64)	265 (62)
Median Progression-free Survival (months)	5.5	3.7
95% CI	4.5, 5.9	3.6, 4.0
HR (95% CI) ª	0.69 (0.58, 0.82)	
P-value ^b	<0.0001	
overall Response Rate ^₀		
confirmed complete or artial overall response, n (%)	99 (23)	31 (7)
95% CI	19.1, 27.2	5.0, 10.1
P-value ^d	<0.0001	
spension (albumin-bound) plus s Stratified Cox proportional hazard Stratified log-rank test stratified b	zard ratio of paclitaxel protein-boun gemcitabine / gemcitabine, ITT = ir d model. yy geographic region (North Americ 30 versus 90 to 100), and presence	ntent-to-treat population

^c Based on Independent Radiological Reviewer Assessment. Chi-square test In exploratory analyses conducted in clinically relevant subgroups with a sufficient number of subjects, the treatment effects on

overall survival were similar to that observed in the overall study

Item: 112455 Eval: X5082623 Cust: CELGENE Size: +39. x +20.5

Folded Size: 3.75 x 1.8125



5 REFERENCES 1. OSHA Hazardous Drugs. OSHA

http://www.osha.gov/SLTC/hazardousdrugs/index.html 16 HOW SUPPLIED/STORAGE AND HANDLING Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a white to to yellow, sterile lyophilized powder supplied as:

NDC 60505-6230-4 100 mg of paclitaxel in a single-dose vial, individually packaged in a carton. Store the vials in original cartons at 20°C to 25°C (68°F to 77°F) Retain in the original package to protect from bright light. Paclitaxel protein-bound particles for injectable suspension albumin-bound) is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹

PATIENT COUNSELING INFORMATION Advise the patient to read the approved patient labeling

(Patient Information). Severe Myelosuppression

Patients must be informed of the risk of low blood cell counts and severe and life-threatening infections and instructed to contact their healthcare provider immediately for fever or evidence of infection [see Warnings and Precautions (5.1), (5.3)] Severe Neuropathy

Patients must be informed that sensory neuropathy occurs frequently with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and patients should advise their healthcare providers of numbress, tingling, pain, or weakness involving the extremities [see Warnings and Precautions (5.2)]. Pneumonitis

Instruct patients to contact their healthcare provider immediately for sudden onset of dry persistent cough, or shortness of breath [see Warnings and Precautions (5.4)]. Severe Hypersensitivity

 Instruct patients to contact their healthcare provider for signs of an allergic reaction, which could be severe and sometimes fatal [see Warnings and Precautions (5.5)]. Common Adverse Reactions

Explain to patients that alopecia, fatigue/asthenia, and myalgia/ arthralgia occur frequently with paclitaxel protein-bound particles for injectable suspension (albumin-bound). Instruct patients to contact their healthcare providers for persis-

tent vomiting, diarrhea, or signs of dehydration [see Adverse Reactions (6)] Embryo-Fetal Toxicity Paclitaxel protein-bound particles for injectable suspension

(albumin-bound) injection can cause fetal harm. Advise patients to avoid becoming pregnant while receiving this drug. Females of reproductive potential should use effective contraception during treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and for at least six months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Warnings and Precautions (5.8) and Use in Specific Populations (8.1, 8.3)]. Advise male patients with female partners of reproductive potential to use effective contraception and avoid fathering a child during treatment with paclitaxel protein-bound particle for injectable suspension (albumin-bound) and for at least three months after the last dose of paclitaxel protein-bound particles for injectable suspension (albumin-bound) [see Use in Specific Populations (8.3)

 Advise patients not to breastfeed while taking paclitaxel proteinbound particles for injectable suspension (albumin-bound) and for two weeks after receiving the last dose [see Use in Specific Populations (8.2)].

Advise males and females of reproductive potential that paclitaxel protein-bound particles for injectable suspension (albuminbound) may impair fertility [see Use in Specific Populations

Manufactured for: Apotex Corp Weston, FL 33326 PACAPOPI.012/PPI.012

Proof B

1/19/2022

PROVIDE A STATE OF CONTROL OF CO Serving Nosco Facilities in Illinois, Texas, Pennsylvania and New York. OK to Print New Proof Required We must have signed proof before we can begin productio This proof is to show size, copy placement and co break. Spot/PMS colors will be matched on press to PMS Book, 4 Color Process Digital Color Guide Extended Gamut Digital Color Guide and/or approve color standards. 4 Color Process proofs are verified to H H Head to Head G7 standards and approved for color match.

PDF/X when correctly rendered in compliance with PDF/X standards no 'x' should appear in any box Please check overprint settings should you see an 'x'

 $-\otimes$

. • • • • • •

The most common side effects of paclitaxel protein-bound particles for injectable suspension (albumin- bound) in people with breast cancer include:
 include:
 hair loss
 numbness, tingling, pain, or weak-
 ness in the hands or feet
 tiredness
 changes in your liver function tests
 nausea